

Addressing Non Pharmacologic Management in Persons Living with Type 2 Diabetes and HIV: It's Easier than Picking the Perfect Bracket

Andrea Levin, PharmD, BCACP
Faculty, South Florida Southeast AETC
Assistant Professor,
Nova Southeastern University College of Pharmacy
March 6, 2019

Disclosures

- The activity planners and speakers do not have any financial relationships with commercial entities to disclose.
- The speakers will not discuss any off-label use or investigational product during the program.
- This slide set has been peer-reviewed to ensure that there are no conflicts of interest represented in the presentation



Objectives

- Interpret laboratory goals for individuals with type
 2 diabetes and HIV
- Identify non pharmacologic treatment options used in the treatment of diabetes
- Design a culturally sensitive and culturally competent non pharmacologic treatment plan in individuals with type 2 diabetes and HIV



Abbreviations

- Type 2 diabetes (T2DM)
- Hemoglobin A1c (HbA1c)
- Antiretroviral therapy (ART)
- Blood glucose (BG)
- Fasting plasma glucose (FPG)
- Fasting blood glucose (FBG)
- Postprandial blood glucose (PPG)
- Self monitoring blood glucose (SMBG)



Statistics


- 30.3 million individuals have diabetes (9.4% of the population)
- 84.1 million Americans have prediabetes
- New-onset T2DM occurs in approximately > 5% of patients with HIV on PIs with
 - 15% develop prediabetes

CDC Data and Statistics. http://www.cdc.gov/diabetes/data/index.html. Accessed January 10, 2019





T2DM Pathophysiology





ADA Testing Criteria

- Consider testing in all adults who are overweight (BMI >25 kg/m² or >23 kg/m² in Asian Americans) with one or more additional risk factors:
 - Physical inactivity
 - First-degree relative with diabetes
 - High-risk race/ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
 - Women delivering a baby >9 lbs or diagnosed with gestational diabetes
 - Hypertension (≥140/90 mmHg or on antihypertensive medication)
 - HDL cholesterol level <35 mg/dL and/or a triglyceride level > 250 mg/dL
 - Women with polycystic ovary syndrome
 - HbA1c ≥5.7%, impaired glucose tolerance or impaired FBG on previous laboratory test
 - Other manifestation associated with insulin resistance (e.g., severe obesity, acanthosis nigricans)
 - History of CVD
- For all patients, testing should begin at 45 years of age.
 - If results are normal, repeat at a minimum of 3-year intervals
 - Perform yearly testing if results indicate prediabetes





Considerations in HIV

- Be aware of HbA1c limitations
- Consideration can be made for using FBG instead of HbA1c
- Testing for T2DM and prediabetes should occur prior to starting ART, at the time of switching ART, and 3-6 months after changing ART therapy
 - If BG is within range, follow up annually
- Concern in switching ART therapy if impaired glucose tolerance develops
- Be mindful of potential drug interactions



ADA Prediabetes vs. T2DM

Prediabetes Classification

• FPG: 100-125 mg/dL

OR

HbA1c: 5.7-6.4%

OR

 2hr postprandial 75 gram oral glucose tolerance test: 140-199 mg/dL

T2DM Diagnosis*

FPG: ≥126 mg/dL

OR

■ HbA1c: ≥6.5%

OR

 Random BG: ≥200 mg/dL with symptoms of hyperglycemia

OR

 2hr postprandial 75 gram oral glucose tolerance test: >200 mg/dL

*Consider limitations of HbA1c

*Two abnormal readings from the same sample to confirm diagnosis





Diabetes Goals*: ADA vs. AACE

ADA

- HbA1c goal: <7%</p>
- FBG goal:
 - 80-130 mg/dL
- Pre meal goal:
 - 80-130 mg/dL
- 2 hr PPG:
 - <180 mg/dL

AACE

- *HbA1c goal:* <u><</u>6.5%
- FBG goal:
 <110 mg/dL</p>

- 2 hr PPG goal:
 - <140 mg/dL</p>

^{*}Patient specific goals may vary



Therapeutic Lifestyle Changes





Physical Activity

- Aerobic physical activity for overall CV health
 - 150 min moderate-intensity
 - At least 3 days/week (there should not be 2 consecutive days without exercise)
 - Muscle-strengthening activity at least 2 days/week



Physical Activity

- Positive effects on blood glucose and HbA1c
 - Consider counseling regarding decrease in blood glucose
 - May predispose patient to hypoglycemia
- Reduces cardiovascular risk
- Contributes to weight loss
- Improves insulin sensitivity





Physical Activity Considerations

- Consider age and exercise history
- Consider initiating low intensity exercise in those with multiple risk factors for CAD with the goal of slow intensification
- Assess patient for contraindications to certain types of exercise
 - Uncontrolled HTN
 - Severe autonomic neuropathy
 - Foot lesions
 - Proliferative retinopathy



Plate Method


Nutrition Facts

Serving Size 1 cup (40g) Servings Per Container 2.5

| Amount Per Serving | |
|-----------------------------------|-----|
| Calories 150 Calories from Fat 10 | |
| % Daily Value* | |
| Total Fat 3g | 4% |
| Saturated Fat 0.5g | 2% |
| Trans Fat 0g | 0% |
| Cholesterol 0mg | 0% |
| Sodium 10mg | 1% |
| Total Carbohydrate 24g | 9% |
| Dietary Fiber 4g | 15% |
| Sugars 1g | |
| Protein 5g | |
| | |
| Vitamin A | 4% |

2%

4%



http://www.choosemyplate.gov/sites/default/files/printablematerials/2013-EatTheMyPlateWay.pdf Accessed February 23, 2019.



Vitamin C

Calcium

Iron

^{*} Percent Daily Values are based on a 2,000 calorie diet. Your daily values may be higher or lower depending on your calorie needs.

Plate Method Considerations

- Cultural competence
- Goal setting
- Hidden sugars/carbohydrates
- What about sugar free?



Monitoring



Blood Glucose Testing

- Glucometer
- Test strips
- Lancing Device and Lancet
- Code Chip (if required)
- Log
- Alcohol swab?
- Gauze?
- Control Solution



Control Solution: When To Use it

- Opening a new box of test strips
- Leaving the test strip container open
- Thinking test strips are damaged
- If test strips have been left in extreme temperatures, humidity, or both
- After dropping the meter
- Test results do not match how you feel
- Wanting to verify technique
- ***Control solution expires***





Glucometer Use

- Obtain glucometer, test strip vial, bandage, lancing device, gauze, and alcohol swab (if needed).
- Verify test strips have not expired
- Wash hands with soap and water or alcohol finger and allow to air dry.
 - Do not blow on finger to dry
- Remove one test strip from the test strip vial and immediately close the vial
- Slide the test strip into the meter with the contact bars end first and facing up into the test port
- Verify that the code display on the glucometer screen matches the code printed on the test strip vial (if applicable)



Glucometer Use

- When the blood drop display appears on the glucometer, lance the side of the finger, not the finger pad.
- To lance the finger, hold the lancet up to the side of the finger and apply some pressure. While applying pressure, press the button and that will activate the lancet



Glucometer Use

- Gently massage finger to obtain blood sample (you can massage the finger prior to lancing)
- Place glucometer up to blood sample. Ensure that sample fills entire window on strip. You will know you have enough blood because an hour glass will appear on the glucometer screen
- Place bandage on finger
- Record values in log or glucometer memory



BG Testing

- Non insulin therapies???
- Basal insulin
 - SMBG recommended
- Basal-bolus insulins
 - SMBG recommended
 - Continuous blood glucose monitoring?





Sharps Disposal**

- Acceptable options:
 - Sharps container (gold standard)
 - Metal can
 - Coffee/paint
 - Thick plastic container
 - Laundry detergent bottle
- Do not discard loose sharps in regular trash or flush down the toilet
 - Do not recycle these items
 - Do not place in clear plastic or glass bottles
- Do not allow sharps to be accessible to others



Other Considerations

- Follow up
 - FPG every 6-12 months or 3 months after ART therapy initiated
 - Annual urinary albumin
- Dilated Eye Exam
 - Annually
- Foot examination
 - Every visit if at high risk for ulcerations
 - Annual examination for everyone

- Dental
 - At least every 6 months
- Immunizations
 - Annual Influenza
 - Pneumonia
 - PCV 13® followed by PPSV23® at least 8 weeks later
 - Hepatitis B series
 - Other vaccine considerations



Summary

- Lifestyle modifications play a key role in the management of T2DM
- Consider the benefits of goal setting
- Consider the patient in decision making



References

- CDC Data and Statistics. http://www.cdc.gov/diabetes/data/index.html. Accessed May 1, 2018.
- American Diabetes Association. Standards of medical care in diabetes-2019. Diabetes Care 2019; 42 Suppl 1.
- Diabetes: Primary Care of Veterans with HIV. https://www.hiv.va.gov/provider/manual-primary-care/diabetes.asp. October 28, 2011.
- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. <u>https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/287/insti-drug-interactions</u>. 2017.
- American Diabetes Association Food and Fitness. http://www.diabetes.org/food-and-fitness/food/what-can-i-eat/food-tips/. Accessed March 1, 2019.





Addressing Non Pharmacologic Management in Persons Living with Type 2 Diabetes and HIV: It's Easier than Picking the Perfect Bracket

Andrea Levin, PharmD, BCACP
Faculty, South Florida Southeast AETC
Assistant Professor,
Nova Southeastern University College of Pharmacy
March 6, 2019